Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,190 across all filing types
Latest filing 2024-05-22 Earnings Release
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated May 22, 2024, from Strides Pharma Science Limited announcing its consolidated financial results for the quarter (Q4FY24) and full year (FY24) ended March 31, 2024. It includes detailed financial highlights such as revenue, EBITDA, gross margin, and adjusted PAT, along with commentary from the Executive Chairperson & Managing Director. The document also mentions a final dividend declaration. The text includes a financial presentation and detailed performance metrics, but it is primarily an initial announcement of quarterly and full-year financial results rather than a full annual report or detailed management discussion. The presence of key financial metrics and highlights for the quarter and full year, along with the announcement of dividend, aligns with the characteristics of an Earnings Release (ER). The document is about 15,000 characters, which is typical for an earnings release with detailed highlights and commentary. Therefore, the most appropriate classification is Earnings Release (ER).
2024-05-22 English
Dividend
Annual Report Classification · 95% confidence The document is a detailed communication from the Board of Directors of Strides Pharma Science Limited dated May 22, 2024, announcing the outcome of a Board Meeting where the audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2024, were approved. It includes the auditors' report from B S R & Co. LLP, which provides an independent auditor's opinion on the consolidated annual financial results for the fiscal year ended March 31, 2024. The document references Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to financial results disclosures. The content includes detailed audit opinions, management responsibilities, and audit procedures, indicating it is the actual audited financial results report rather than a mere announcement or certification. The length (15,000 characters) and the inclusion of substantive financial and audit information confirm it is the full Annual Report or Annual Financial Results document. Therefore, the appropriate classification is Annual Report (10-K).
2024-05-22 English
Financial Result Updates
Annual Report Classification · 95% confidence The document is a detailed communication from the Board of Directors of Strides Pharma Science Limited dated May 22, 2024, announcing the outcome of a Board Meeting where the audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2024, were approved. It includes the auditors' report from B S R & Co. LLP, which provides an independent auditor's opinion on the consolidated annual financial results for the fiscal year ended March 31, 2024. The document references compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and contains substantive financial data, audit opinions, and management responsibilities. It also mentions the recommendation of a final dividend for the financial year ended March 31, 2024. The length of the document (15,000 characters) and the inclusion of the full auditor's report and financial results indicate this is the actual Annual Report or Annual Financial Results filing, not merely an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K equivalent) as it covers the full financial performance and audit results for the fiscal year.
2024-05-22 English
Press Release
Capital/Financing Update Classification · 85% confidence The document is a press release announcing that Strides Pharma Science Limited has received USFDA approval for a specific pharmaceutical product. It contains no financial statements, regulatory filings, or detailed financial data. The document is relatively short (4116 characters) and serves as a public announcement of a corporate event (product approval). It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is not a report publication announcement since it is not announcing the release of a report but rather a corporate news update. The best fitting category is Capital/Financing Update (CAP) as it relates to a significant corporate development impacting the company's product portfolio and potential market expansion, which is often classified under capital or corporate updates in financial databases.
2024-05-22 English
Loss of Share Certificates
Transaction in Own Shares Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding the issuance of a duplicate share certificate for a shareholder who lost the original. It references compliance with SEBI regulations and includes details about the shareholder and certificate numbers. The content is an announcement about a share certificate issue, not a financial report, earnings release, or management discussion. It does not contain financial statements or performance data. The document is primarily an official notification related to share certificates, which fits best under the category of Transaction in Own Shares (POS), as it involves share certificate issuance and related procedural updates.
2024-05-21 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2024-05-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.